EnteroTarget is a clinical stage company founded in 2018 based on an exclusive license to the patent “Rectal Insulin for treatment of inflammatory bowel disease”, which is granted in 15 European countries and in the US (pending in Canada). The patent is owned by University of Copenhagen and has two EnteroTarget founders among the inventors.

EnteroTarget’s product is named Enterocalm, which has topically acting insulin as the active pharmaceutical ingredient. The first version is EnteroCalm Enema which is to be followed by an orally administered version delivering topically acting insulin to the colon utilizing EnteroTarget’s proprietary capsule technology, the EnteroShuttle (patent pending).

We are partnering up with investors to bring the therapy to market with pouchitis and ulcerative colitis as the primary medical indications and with Crohn’s disease as a potential additional indication. 

Currently, we are running phase 1 clinical trials and are preparing for a clinical phase 2 to meet the milestones in our ambitious business plan.

EnteroTarget

Org chart

Teams

Offices